This study aims to evaluate the potential of delta‐He as a significant predictive and prognostic factor in non‐small cell lung cancer (NSCLC) patients treated with PD‐1/PD‐L1 inhibitors. Here, PDCD1 is linked to non-small cell lung carcinoma.